Constantinidou, Anastasia

Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy

Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 342

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

Radiogenomics for Precision Medicine With a Big Data Analytics Perspective

Panayides, A. S., Pattichis, M. S., Leandrou, S., Pitris, C., Constantinidou, A., & Pattichis, C. S. (2019) · IEEE Journal of Biomedical and Health Informatics

Radiomics and Machine Learning in Medical ImagingArtificial Intelligence in Healthcare and Education

Cited by 66